228 related articles for article (PubMed ID: 23196793)
21. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.
Rekhtman N; Pietanza CM; Sabari J; Montecalvo J; Wang H; Habeeb O; Kadota K; Adusumilli P; Rudin CM; Ladanyi M; Travis WD; Joubert P
Mod Pathol; 2018 Jan; 31(1):111-121. PubMed ID: 28884744
[TBL] [Abstract][Full Text] [Related]
22. [Large cell carcinoma, lymphoepithelioma-like carcinoma, NUT carcinoma].
Copin MC
Ann Pathol; 2016 Jan; 36(1):24-33. PubMed ID: 26739900
[TBL] [Abstract][Full Text] [Related]
23. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
24. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
[TBL] [Abstract][Full Text] [Related]
25. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
26. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
27. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
28. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.
Conde E; Angulo B; Izquierdo E; Muñoz L; Suárez-Gauthier A; Plaza C; Dominguez N; Torres M; Madrigal L; Rubio-Viqueira B; Belda-Iniesta C; Hidalgo M; López-Ríos F
Histopathology; 2013 Mar; 62(4):609-16. PubMed ID: 23379755
[TBL] [Abstract][Full Text] [Related]
29. Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
Woischke C; Jung P; Jung A; Kumbrink J; Eisenlohr S; Auernhammer CJ; Vieth M; Kirchner T; Neumann J
J Pathol Clin Res; 2021 Jan; 7(1):75-85. PubMed ID: 33197299
[TBL] [Abstract][Full Text] [Related]
30. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
31. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
32. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.
Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM
Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762
[TBL] [Abstract][Full Text] [Related]
34. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Pelosi G; Fabbri A; Papotti M; Rossi G; Cavazza A; Righi L; Tamborini E; Perrone F; Settanni G; Busico A; Testi MA; Maisonneuve P; De Braud F; Garassino M; Valeri B; Sonzogni A; Pastorino U
J Thorac Oncol; 2015 Nov; 10(11):1560-9. PubMed ID: 26317919
[TBL] [Abstract][Full Text] [Related]
35. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
[TBL] [Abstract][Full Text] [Related]
36. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
37. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.
Karlsson A; Brunnström H; Lindquist KE; Jirström K; Jönsson M; Rosengren F; Reuterswärd C; Cirenajwis H; Borg Å; Jönsson P; Planck M; Jönsson G; Staaf J
Oncotarget; 2015 Sep; 6(26):22028-37. PubMed ID: 26124082
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
39. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
